الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
Hodgkin lymphoma (HL) is a lymph node based malignancy originating from B cells. It’s characterized by the presence of Reed-Sternberg (RS) cells. It comprises 1% of all cancer cases and 14% of all lymphomas worldwide. In Egypt, lymphoma is considered the fourth most common tumor in adults and HL represents 23.4% of all lymphomas.
According to the World Health Organization (WHO) classification, HL is divided into two subgroups: (classical Hodgkin’s lymphoma) (cHL) and Nodular Lymphocyte Predominant Hodgkin’s lymphoma (NLPHL).
Classical hodgkin’s lymphoma accounts for 95% of all HLs and can be subdivided into four histological subtypes including nodular sclerosis, mixed cellularity, lymphocyte depletion and lymphocyte-rich lymphoma.
The management of HL includes chemotherapy and radiotherapy and is determined according to the staging and risk factors. The most common regimen used as first line is adriamycin/doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD).